The Valeant Drama Continues

Bloomberg is out with a late night, exclusive article, talking shit about VRX, giving Bill Ackman nightmares. Don’t you know he barely sleeps after all of the grief that fucker Ron Johnson gave him after the JCP fiasco? Last thing he needs is a $3 billion position turn into fairy dust, a la Enron, the Canadian pharma version.

Actually, the documents BBG secured are pretty damning, painting a fairly vivid picture of a boiler room type operation at VRX. For the record, I would expect nothing less, being that it’s domiciled in the traitorous soil where loyalists took root and plotted to burn down our fucking whited house, all for God and Country of course.

Philidor Rx Services LLC, which fills prescriptions for Valeant Pharmaceuticals International Inc., instructed employees to submit claims under different pharmacy identification numbers if an insurer rejected Philidor’s claim — to essentially shop around for one that would be accepted.

Employees were to first submit paperwork with Philidor’s national provider identifier, or NPI, and if that didn’t work were to then try with the NPIs of partner pharmacies, according to a Philidor training manual. “We have a couple of different ‘back door’ approaches to receive payment from the insurance company,” said the manual, dated October 2014.

“You will run across several insurances that we are not contracted with,” according to the document, which was obtained by Bloomberg News. In that case, “submit the NPI for our partner in California, West Wilshire Pharmacy,” the manual said. “There is a good chance they are contracted.” If that was denied, the next step was to “add the Cambria Central Fill insurance and run that as the primary,” apparently referring to a pharmacy in Philadelphia. “They should then get a paid claim and then Cambria, another one of our partners, will reimburse us.”

The document’s guidance on NPIs was first reported by the Wall Street Journal.

Valeant’s relationship with Philidor is at the heart of questions being raised by prosecutors, lawmakers and investors about the drugmaker’s operations and practices. Laval, Quebec-based Valeant has lost almost $10 billion in market value since a Wall Street short-seller on Oct. 21 suggested the company was using Philidor to pump up retail sales and engage in Enron-style accounting tactics. Valeant has denied the allegations.

Ron Hutcheson, a spokesman for Philidor, said the pharmacy is “the patient’s advocate in seeking to ensure that they receive the medication that was prescribed by their doctor at the lowest possible cost to them. This includes following up with insurance companies on behalf of patients.”

Calls placed after regular business hours to Valeant and West Wilshire in Los Angeles weren’t immediately answered. At Cambria Pharmacies, Stephen Bailkin, a manager, said, “I can’t imagine why anyone would be using my NPI number.” He declined to answer questions about Philidor and its relationship with Cambria.

I expect the stock to come under pressure tomorrow. Bill “Montauk” Ackman has his work cut out for him during his 10/30 morning presentation to defend these rascals.